GeneTex, Inc.
6.6.2023 15:05:40 CEST | ACCESS Newswire | Press release
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money19.11.2026 18:01:00 CET | Press release
THE HAGUE, NL / ACCESS Newswire / November 19, 2026 / The Global Anti-Scam Alliance (GASA), in collaboration with Outseer, today released the Global State of Scams 2026 report. Based on a survey of 58,900 adults across 42 markets, the report examines how often people encounter scams, how they respond, and the financial and emotional impact on those affected. In the past 12 months, 64% of adults worldwide encountered a scam and 9% lost money. Shopping, investment, and unexpected money scams were among the types people most often interacted with. In Africa, 21% of adults lost money to a scam, more than double the global rate. The research also highlights the emotional toll of scams. Among people who lost money, 69% reported a significant or moderate impact on their mental wellbeing, 20% reported increased tension at home, and 16% said they could not pay for essentials such as rent or groceries. Among those who did not report the scam to an organization, the most common reason was uncerta
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself19.11.2026 15:00:00 CET | Press release
WARSAW, PL / ACCESS Newswire / November 19, 2026 / Polcode, a software development company that has helped businesses across North America and Europe modernize their technology since 2006, launched its new website at polcode.com this week. Timed to the company's 20th anniversary, the launch is more than a redesign. It applies the same modernization approach Polcode brings to client systems every day to its own brand. For 20 years, Polcode has been the team businesses call when software stops keeping up with the business: aging platforms, tangled integrations, and tools nobody dares touch. So when it came time to rebuild its own website, the question was fair. Would a company that modernizes for others hold itself to the same standard? The new site is Polcode's answer, serving as both a showcase of what the company does and an example of it. We spend a lot of time helping businesses move beyond systems that no longer reflect where they're headed. At some point, we had to ask ourselves t
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval19.11.2026 13:45:00 CET | Press release
CALGARY, AB / ACCESS Newswire / November 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has completed registration under the Compliance Instrument Tracking System Service (CITSS), enabling the Company to participate directly in California's regulated compliance carbon market. This milestone elevates Karbon-X's North American trading infrastructure, enabling the Company to directly source, hold, and transact compliance allowances and eligible offset credits, positioning the Company to capture trading margins and recurring commercial opportunities from California's ongoing compliance demand. Unlike voluntary carbon markets, California's Cap-and-Invest Program is backed by state regulation requiring covered entities to surrender eligible compliance instruments against their emissions obligations, creating recurring regulatory demand for allowances and eligible offset credits. California's pro
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor18.11.2026 15:30:00 CET | Press release
DETROIT, MI / ACCESS Newswire / November 18, 2026 / Leggett Dynamics has won a 2026 Automotive News PACE Pilot Award for its Smart Brushless Motor. This next-generation motion system simplifies vehicle integration, improves performance and supports the industry's transition to software-defined vehicles (SDVs). Leggett Dynamics' Smart Brushless Motor streamlines motion-control architecture by operating with or without a seat-level electronic control unit (ECU). The system enables direct communication between the vehicle-level ECU and individual actuators, supporting more centralized and zonal vehicle architectures while reducing packaging size, weight and wiring complexity. It also improves noise, vibration and harshness (NVH), durability, and electromagnetic compatibility (EMC). "As automakers transition to software-defined vehicles, they are looking for solutions that reduce complexity without compromising performance," said Julien Rea, VP of Global Innovation and Engineering at Legge
Proxymity Unveils MiKaDiv Compliance Solution for Issuers Ahead of New German Tax Regime18.11.2026 08:30:00 CET | Press release
FRANKFURT AM MAIN, DE / ACCESS Newswire / November 18, 2026 / Proxymity, the digital investor communications platform, is set to launch its MiKaDiv Compliance Solution as Germany's new dividend reporting regime takes effect in January 2027, giving German issuers a single place to manage their new obligations to the Federal Central Tax Office (BZSt). From 1 January 2027, dividends paid by listed German companies will carry an additional reporting step: the company must pass details of its shareholders to the BZSt. SRD II, transposed into German law under Section 67d of the German Stock Corporation Act, (AktG) took effect in 2020 and gave issuers the right to identify their investors, including foreign investors held through nominee accounts. MiKaDiv now makes it a requirement. The first reports are expected early in the 2027 AGM season, as issuers seek approval for their dividends. Proxymity is the leading provider of shareholder identification to German issuers, handling more than 40%
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
